Designing and building oncolytic viruses

Justin Maroun, Miguel Muñoz-Alía, Arun Ammayappan, Autumn Schulze, Kah Whye Peng, Stephen Russell

Research output: Contribution to journalReview articlepeer-review

61 Scopus citations


Oncolytic viruses (OVs) are engineered and/or evolved to propagate selectively in cancerous tissues. They have a dual mechanism of action; direct killing of infected cancer cells cross-primes anticancer immunity to boost the killing of uninfected cancer cells. The goal of the field is to develop OVs that are easily manufactured, efficiently delivered to disseminated sites of cancer growth, undergo rapid intratumoral spread, selectively kill tumor cells, cause no collateral damage and pose no risk of transmission in the population. Here we discuss the many virus engineering strategies that are being pursued to optimize delivery, intratumoral spread and safety of OVs derived from different virus families. With continued progress, OVs have the potential to transform the paradigm of cancer care.

Original languageEnglish (US)
Pages (from-to)193-213
Number of pages21
JournalFuture Virology
Issue number4
StatePublished - Apr 2017


  • cancer therapy
  • oncolytic immunotherapy
  • oncolytic virotherapy
  • virus engineering
  • virus targeting

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Designing and building oncolytic viruses'. Together they form a unique fingerprint.

Cite this